Lv4
490 积分 2024-11-16 加入
Role of lifestyle and glucagon‐like peptide‐1 receptor agonists for weight loss in obesity, type 2 diabetes and steatotic liver diseases
2小时前
已完结
The dual glucose‐dependent insulinotropic polypeptide/glucagon‐like peptide‐1 receptor agonist tirzepatide effects on body weight evolution, adiponectin, insulin and leptin levels in the combination of obesity, type 2 diabetes and menopause in mice
2小时前
已完结
Why does GLP‐1 agonist combined with GIP and/or GCG agonist have greater weight loss effect than GLP‐1 agonist alone in obese adults without type 2 diabetes?
2小时前
已完结
FGF19 and FGF21 serum concentrations in human obesity and type 2 diabetes behave differently after diet- or surgically-induced weight loss
2小时前
已完结
Pharmacological actions of FGF19 and FGF21 revealed
2小时前
已完结
Stress-induced FGF21 and GDF15 in obesity and obesity resistance
2小时前
已完结
GDF15 is a major determinant of ketogenic diet-induced weight loss
2小时前
已完结
A multicenter, open‐label, single‐arm trial of the long‐term safety of empagliflozin treatment for refractory diabetes mellitus with insulin resistance (EMPIRE‐02)
1个月前
已完结
GDF15 is still a mystery hormone
1个月前
已完结
皖公网安备34019202002308
